<DOC>
	<DOCNO>NCT01970553</DOCNO>
	<brief_summary>Phase I multicenter , open-label , clinical pharmacokinetic study PM01183 combination gemcitabine non-heavily pretreated patient select advanced solid tumor determine maximum tolerate dose ( MTD ) recommend dose ( RD ) PM01183 combination gemcitabine , characterize safety profile feasibility combination patient select advanced solid tumor , characterize pharmacokinetics ( PK ) , obtain preliminary information clinical antitumor activity non-heavily pretreated select solid tumor patient evaluate pharmacogenomics ( PGx ) tumor sample patient expose , order assess potential marker response and/or resistance .</brief_summary>
	<brief_title>Escalating Doses PM01183 Combination With Gemcitabine Patients With Specific Unresectable Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Voluntarily write informed consent Age : 18 75 year ( inclusive ) Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) ≤ 1 Life expectancy ≥ 3 month Patients histologically/cytologically confirm diagnosis advance disease follow tumor : 1 . Breast cancer 2 . Epithelial ovarian cancer ( include primary peritoneal disease and/or fallopian tube carcinoma and/or endometrial adenocarcinoma ) 3 . Stromal uterine sarcoma 4 . Nonsmall cell lung cancer ( NSCLC ) 5 . Platinumrefractory relapse germ cell tumor 6 . Adenocarcinoma exocrine pancreas 7 . Biliary tract adenocarcinoma 8 . Adenocarcinoma carcinoma unknown primary site 9 . Advanced unresectable mesothelioma At least three week since last anticancer therapy , include radiation therapy ( RT ) Adequate bone marrow , renal , hepatic , metabolic function Left ventricular ejection fraction ( LVEF ) echocardiography ( ECHO ) multiplegated acquisition ( MUGA ) within normal range ( accord institutional standard ) . Women childbearing potential must negative serum pregnancy test study entry . Both woman men must agree use medically acceptable method contraception throughout treatment period six week discontinuation treatment . Concomitant diseases/conditions : History presence unstable angina , myocardial infarction , congestive heart failure , clinically significant valvular heart disease within last year . Symptomatic uncontrolled arrhythmia Ongoing chronic alcohol consumption , cirrhosis Active uncontrolled infection . Known human immunodeficiency virus ( HIV ) infection . Any major illness , Investigator 's judgment Brain metastases leptomeningeal disease involvement Men woman childbearing potential use effective method contraception Patients radiation therapy 35 % bone marrow History previous bone marrow and/or stem cell transplantation Prior treatment gemcitabinecontaining therapy advance disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>lurbinectedin</keyword>
	<keyword>PM01183</keyword>
	<keyword>tumor</keyword>
	<keyword>cancer</keyword>
	<keyword>Pharma Mar</keyword>
</DOC>